Focus

Opthea is committed to improving vision in patients suffering from retinal eye diseases.

We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies.

OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in Phase 2 wet AMD and DME clinical trials.

LEARN MORE

Disease

Wet AMD is the leading cause of blindness in the developed world in people aged over 50 years. It is caused by the abnormal growth and leakage of blood vessels at the back of the eye, which causes degeneration of the retina and vision loss.

Learn More

Technology

Opthea’s technology is centred on two members of the Vascular Endothelial Growth Factor (VEGF) family of proteins, VEGF-C and VEGF-D, and their activation of VEGF receptors.These proteins promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3, and lymphatic vessel development (lymphangiogenesis), by activation of VEGFR-3.

Learn More

Opportunity

Both wet AMD and DME are associated with vascular dysfunction and fluid accumulation at the back of the eye in a region of the central retina or ‘macula’ that is needed for sharp, central vision. Vessel growth and vascular leakage are primarily driven by members of the vascular endothelial growth factor (VEGF) family, which comprises 5 members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF).

Learn More

OPT-302

OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Learn More

Trials

Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 in wet AMD patients.Opthea has completed enrolling patients in a Phase 2b clinical trial for patients with wet AMD and is currently enrolling patients in a Phase 2a clinical trial in patients with DME.

wet AMDDME

With trials progressing
and initial data
looking promising,
we are confident
the end of this
debilitating
disease is within
sight.

Opthea Researcher

Announcements

S&P DJI Announces March 2019 Quarterly Rebalance

8th March 2019

S&P Dow Jones Indices announced today the changes in the S&P/ASX indices, effective at the open of trading on March 18, 2019.

Read More

Opthea Ph2b Trial Advances With 2nd Positive Safety Review

7th March 2019

Opthea Limited (ASX:OPT) is pleased to announce that the independent Data and Safety Monitoring Board (DSMB) for the Company’s ongoing Phase 2b study of OPT-302.

Read More

Opthea Confirms Final Patient Enrolment in Wet AMD Clinical Trial

26th November 2018

Opthea are pleased to report the enrollment of the last patient in the ongoing Phase 2b trial of OPT302 for wet age-related macular degeneration (AMD)…

Read More

Opthea Provides Update for wet AMD and DME on Key Opinion Forum

29th October 2018

Opthea Provides Update on Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum: October 2018, Opthea is pleased to provide an update on “Beyond anti-VEGF-A…

Read More

ALL ANNOUNCEMENTS